文献速递浆细胞疾病

AKT信号抑制FOXO转录因子与GSK3激酶在多发性骨髓瘤中的抑瘤功能

AKT signaling restrains tumor suppressive functions of FOXO transcription factors and GSK3 kinase in multiple myeloma.
PubMed 文献 · Blood Adv · 2020-01-01

多发性骨髓瘤中AKT信号持续激活并依赖FOXO转录因子和GSK3发挥促存活作用。研究显示,阻断AKT可诱导骨髓瘤细胞死亡和周期阻滞,该效应依赖FOXO和GSK3。AKT通过抑制FOXO/GSK3介导的MCL1降解来稳定MCL1,阻断AKT可增敏MCL1靶向BH3模拟物。

要点

  • 阻断AKT信号可诱导骨髓瘤细胞死亡和细胞周期阻滞,该效应依赖FOXO转录因子和GSK3。
  • AKT通过抑制FOXO和GSK3介导的MCL1降解来稳定抗凋亡蛋白MCL1。
  • 阻断AKT信号可显著增敏骨髓瘤细胞对MCL1靶向BH3模拟物的反应。

核心结论

  • AKT活性通过抑制FOXO和GSK3的抑瘤功能来稳定MCL1,从而维持多发性骨髓瘤细胞存活。

研究设计与样本

  • 研究在多发性骨髓瘤细胞中开展,基于基因表达谱分析定义了FOXO抑制基因集,并在大型患者队列中评估其预后意义。

主要发现

  • 在多发性骨髓瘤细胞中阻断AKT信号可诱发细胞死亡和细胞周期阻滞,且关键依赖FOXO转录因子和GSK3。
  • 基于基因表达谱定义的FOXO抑制基因集在大型多发性骨髓瘤患者队列中具有预后意义,提示AKT介导的基因激活与较差的总生存相关。
  • AKT信号通过抑制FOXO和GSK3介导的MCL1周转来稳定抗凋亡蛋白MCL1。
  • 阻断AKT信号可显著增敏多发性骨髓瘤细胞对MCL1靶向BH3模拟物(目前处于临床开发中)的反应。

临床怎么用

  • 研究提示靶向AKT信号通路可能通过解除对FOXO和GSK3的抑制来发挥抗骨髓瘤作用。
  • AKT抑制剂与MCL1靶向BH3模拟物联合可能提高多发性骨髓瘤靶向治疗疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The phosphatidylinositide-3 kinases and the downstream mediator AKT drive survival and proliferation of multiple myeloma (MM) cells. AKT signaling is active in MM and has pleiotropic effects; however, the key molecular aspects of AKT dependency in MM are not fully clear. Among the various downstream AKT targets are the Forkhead box O (FOXO) transcription factors (TFs) and glycogen synthase kinase 3 (GSK3), which are negatively regulated by AKT signaling. Here we show that abrogation of AKT signaling in MM cells provokes cell death and cell cycle arrest, which crucially depends on both FOXO TFs and GSK3. Based on gene expression profiling, we defined a FOXO-repressed gene set that has prognostic significance in a large cohort of patients with MM, indicating that AKT-mediated gene activation is associated with inferior overall survival. We further show that AKT signaling stabilizes the antiapoptotic myeloid cell leukemia 1 (MCL1) protein by inhibiting FOXO- and GSK3-mediated MCL1 turnover. In concordance, abrogation of AKT signaling greatly sensitized MM cells for an MCL1-targeting BH3-mimetic, which is currently in clinical development. Taken together, our results indicate that AKT activity is required to restrain the tumor-suppressive functions of FOXO and GSK3, thereby stabilizing the antiapoptotic protein MCL1 in MM. These novel insights into the role of AKT in MM pathogenesis and MCL1 regulation provide opportunities to improve targeted therapy for patients with MM.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Bloedjes TA, de Wilde G, Maas C, et al. AKT signaling restrains tumor suppressive functions of FOXO transcription factors and GSK3 kinase in multiple myeloma. Blood Adv. 2020. PMID: 32898245. doi:10.1182/bloodadvances.2019001393

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。